药物发现
鉴定(生物学)
计算生物学
药物开发
优先次序
生物标志物发现
基因组学
计算机科学
药品
生物信息学
生物
基因组
蛋白质组学
过程管理
药理学
基因
工程类
遗传学
植物
作者
Bram Van de Sande,Joon Sang Lee,Euphemia Mutasa-Gottgens,Bartholomew J. Naughton,Wendi Bacon,Jonathan Manning,Yong Wang,Jack Pollard,Melissa G. Mendez,Jon Hill,Namit Kumar,Xiaohong Cao,Xiao Chen,Mugdha Khaladkar,Ji Wen,Andrew R. Leach,Edgardo A. Ferrán
标识
DOI:10.1038/s41573-023-00688-4
摘要
Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry.
科研通智能强力驱动
Strongly Powered by AbleSci AI